Dyne Therapeutics to Participate in Upcoming Investor Conferences
Live webcasts and 90-day replays will be available in the Investors & Media section of Dyne’s website for the conference presentations.
Rhea-AI Summary
Dyne Therapeutics (DYN)/b) will participate in three healthcare investor conferences in September 2026, each featuring a management fireside chat in New York, NY.Events include the 2026 Cantor Global Healthcare Conference on September 11 at 10:20 a.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 9:15 a.m. ET, and the Baird 2026 Global Healthcare Conference on September 15 at 10:50 a.m. ET. Live webcasts and 90-day replays will be available in the Investors & Media section of Dyne’s website.
Positive
- None.
Negative
- None.
News Market Reaction – DYN
In the Sep 2 session, DYN gained 0.16%, reflecting a mild positive market reaction. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
- 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NY
- Morgan Stanley 24th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY
- Baird 2026 Global Healthcare Conference, fireside chat on Tuesday, September 15, 2026 at 10:50 a.m. ET in New York, NY
A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
